Radiopharmaceutical Therapeutic Market Share Insights | 2031
放射性药物治疗市场规模 预计将从 2023 年的 27.1 亿美元增至 2031 年的 73.0 亿美元。预计 2023-2031 年市场复合年增长率将达到 13.1%。在核医学成像设备中引入人工智能算法来优化治疗计划很可能仍是放射性药物治疗市场的一个主要趋势。
放射性药物治疗市场分析
医学成像行业的快速扩张、对个性化医疗的日益增长的偏好、放射性药物治疗的突破、改进靶向策略的技术发展以及政府投资的增加是推动放射性药物治疗市场收入的主要因素。
放射性药物治疗市场概况
用于治疗癌症和其他疾病的含有放射性同位素的药物被称为放射性药物疗法。为了尽量减少对健康组织的损害,这些放射性药物被制成专门针对并直接向疾病部位发射高剂量辐射。
由于核医学技术的发展、对更好治疗方案的需求不断增长以及慢性病患病率的上升,放射性药物治疗市场前景光明。此外,个性化医疗和靶向治疗的接受度不断提高预计将支持市场扩张。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
放射性药物治疗市场:
Radiopharmaceutical Therapeutic Market: Strategic Insights
Radiopharmaceutical Therapeutic Market
-
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cagr.png)
CAGR (2023 - 2031)
13.1%
-
Market Size 2023
US$ 2.71 Billion
-
Market Size 2031
US$ 7.30 Billion
Key Players
- Cardinal Health
- Bayer
- Novartis
- Jubilant DraxImage Inc.
- Curium
- Yantai Dongcheng Pharmaceutical Group
- Lantheus
- Q BioMed
- Telix Pharmaceuticals
- Radiopharm Theranostics
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 亚太地区(中国、日本、韩国、印度、澳大利亚、亚太地区其他地区)
- 欧洲(德国、法国、英国、意大利、俄罗斯、欧洲其他地区)
- 中东和非洲(沙特阿拉伯、阿联酋、南非、中东和非洲其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
Market Segmentation
产品类型(锝-99m、铊-201、镓-68、碘-131、铜-64 等)
治疗类型(α 发射体、β 发射体和近距离放射治疗同位素)
应用(肿瘤学、神经病学、心脏病学等)
最终用户(医院、肿瘤诊所等)
Radiopharmaceutical Therapeutic Market: Strategic Insights
-
CAGR (2023 - 2031)13.1% -
Market Size 2023
US$ 2.71 Billion -
Market Size 2031
US$ 7.30 Billion
![](https://www.theinsightpartners.com/assets/images/rd_int_img/tip-logo.jpg)
Key Players
- Cardinal Health
- Bayer
- Novartis
- Jubilant DraxImage Inc.
- Curium
- Yantai Dongcheng Pharmaceutical Group
- Lantheus
- Q BioMed
- Telix Pharmaceuticals
- Radiopharm Theranostics
Regional Overview
![](https://www.theinsightpartners.com/assets/images/rd_int_img/ig-regional.png)
- 北美(美国、加拿大、墨西哥)
- 亚太地区(中国、日本、韩国、印度、澳大利亚、亚太地区其他地区)
- 欧洲(德国、法国、英国、意大利、俄罗斯、欧洲其他地区)
- 中东和非洲(沙特阿拉伯、阿联酋、南非、中东和非洲其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
Market Segmentation
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_danger.png)
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_warning.png)
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_primary.png)
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_warning.png)
复合年增长率(2023 - 2031)13.1%- 2023 年市场规模
27.1 亿美元 - 2031年市场规模
73亿美元
![](https://www.theinsightpartners.com/assets/images/rd_int_img/tip-logo.jpg)
市场动态
- 靶向治疗越来越受欢迎
- 癌症发病率不断上升
- 临床试验数量不断增加
- 市场参与者之间的战略联盟
关键人物;主力;重要一员
- 康德乐
- 拜耳
- 诺华
- Jubilant DraxImage Inc.
- 锔
- 烟台东诚医药集团
- 兰瑟斯
- Q 生物医学
- Telix 制药公司
- 放射药物治疗诊断学
区域概况
![](https://www.theinsightpartners.com/assets/images/rd_int_img/ig-regional.png)
- 北美
- 亚太地区
- 欧洲
- 中东和非洲
- 南美洲和中美洲
市场细分
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_danger.png)
- 锝-99m
- 铊-201
- 镓-68
- 碘-131
- 铜-64
- 其他的
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_warning.png)
- 阿尔法辐射源
- β 辐射源
- 近距离放射治疗同位素
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_primary.png)
- 肿瘤学
- 神经病学
- 心脏病学
- 其他的
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_warning.png)
- 医院
- 肿瘤诊所
- 其他的
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
放射性药物治疗市场驱动因素和机遇
靶向治疗日益普及,推动市场增长
靶向治疗是用于局部和全身癌症治疗的最新和不断发展的技术。临床前研究和临床试验表明,发射α粒子的放射性核素会杀死目标癌细胞,而不会损害附近的健康细胞。225Ac 和 227Th 是附着在单克隆抗体上的发射α粒子的放射性同位素,可通过局部释放高剂量的辐射选择性地识别和杀死癌细胞。α辐射适用于杀死血管和淋巴系统中孤立的癌细胞,并通过扰乱肿瘤毛细血管网络来靶向和杀死肿瘤毛细血管内皮细胞来使肿瘤消退。镭-223 二氯化物α疗法是唯一获批的内部发射α粒子的放射性同位素癌症治疗概念。靶向放射性核素治疗是靶向治疗类别中的一种。全身给药的靶向放射治疗结合了癌细胞靶向的特异性和已知的电离辐射抗肿瘤作用,有可能同时根除原发性肿瘤部位和已扩散到全身的癌症,包括诊断成像无法检测到的恶性细胞群。有两种商业上批准的放射免疫治疗药物,钇-90 伊布替莫单抗(Zevalin;Biogen-Idec Pharmaceuticals,2002 年获批)和碘-131 托西莫单抗(BEXXAR,葛兰素史克,2003 年获批),这两种药物都用于治疗惰性 B 细胞淋巴瘤和相关癌症。因此,在癌症治疗中优先使用靶向疗法推动了放射性药物治疗市场的增长。
企业间战略联盟有利于市场增长
战略联盟和协议有助于发现癌症研究领域的突破性解决方案,同时与拥有相同愿景的企业建立更深层次的关系。战略联盟可以潜在地增加公司的收入和盈利能力,并通过增加产品组合帮助公司在放射治疗领域取得进步。以下是一些正在进行战略联盟的公司:
2021 年 6 月,Nimble Therapeutics 与 RayzeBio 达成战略研究合作,旨在发现和开发用于治疗癌症的新型肽类放射性药物。RayzeBio 拥有开发和销售合作中发现的肽类药物的独家权利,并有权选择进一步扩大合作范围,以涵盖其他目标。
2024 年 1 月,Lantheus Holdings, Inc. 与 Perspective Therapeutics, Inc. 达成多项战略协议,后者是一家开创全身癌症先进治疗解决方案的放射性制药公司。根据协议,Lantheus 可以选择独家授权 Perspective 的 Pb212-VMT-⍺-NET,这是一种用于治疗神经内分泌肿瘤的临床阶段 alpha 疗法,还可以选择使用 Perspective 的创新领先平台技术共同开发某些针对前列腺癌的早期治疗候选药物。这些战略交易将扩大 Lantheus 的产品线,并为神经内分泌肿瘤和前列腺癌的重大进展开辟道路。
2024 年 3 月,Ratio Therapeutics Inc. 扩大了与 PharmaLogic 的制造协议,PharmaLogic 是一家专注于放射性药物生产和分销的世界级合同开发和制造组织。此次合作大大加快了 Ratio 下一代放射疗法的开发和商业化,标志着 Ratio 推进成纤维细胞活化蛋白-α (FAP) 靶向放射治疗候选药物的关键组成部分。
放射性药物治疗市场报告细分分析
有助于得出放射性药物治疗市场分析的关键部分是产品类型、治疗类型、应用和最终用户。
- 根据产品类型,放射性药物治疗市场分为锝-99m、铊-201、镓-68、碘-131、铜-64 等。锝-99m 部分在 2023 年占据最大市场份额,预计在预测期内将实现最高复合年增长率。
- 根据治疗类型,市场分为 α 发射体、β 发射体和近距离放射治疗同位素。β 发射体部分在 2023 年占据了最大的市场份额,预计在预测期内将实现最高的复合年增长率。
- 就应用而言,市场分为肿瘤学、神经病学、心脏病学等。肿瘤学领域在 2023 年占据最大的市场份额,预计在预测期内将实现最高的复合年增长率。
- 根据最终用户,放射性药物治疗市场分为医院、肿瘤诊所和其他。医院部门在 2023 年占据最大的市场份额,预计在预测期内将实现最高的复合年增长率。
放射性药物治疗市场份额按地区分析
放射性药物治疗市场报告的地理范围主要分为五个地区:北美、亚太、欧洲、中东和非洲、南美和中美。
北美在放射性药物治疗市场占据主导地位。该地区致力于技术创新并采用尖端成像模式,巩固了其在放射性药物治疗领域的卓越地位。用于治疗的靶向放射性药物将放射性核素直接输送到身体任何部位的肿瘤,因此,靶向放射性药物引发了人们对治疗卵巢癌的临床开发的兴趣。美国国家癌症研究所利用放射性药物在卵巢癌临床应用方面的先前经验,进一步开发了结合放射性药物,未来可能会考虑用于化疗难治性卵巢癌患者的治疗。因此,上述因素促成了北美在放射性药物治疗市场的主导地位。
放射性药物治疗市场新闻和最新发展
放射性药物治疗市场通过收集一级和二级研究后的定性和定量数据进行评估,其中包括重要的公司出版物、协会数据和数据库。以下是放射性药物治疗市场的发展和战略列表:
- 拜耳与 Bicycle Therapeutics 达成战略合作,旨在发现、开发、制造和商业化肿瘤领域新型靶向放射性核素疗法。(来源:拜耳股份公司,新闻稿,2023 年)
- 诺华获得欧盟委员会批准,用于靶向放射性配体疗法 Pluvicto(INN:镥(177Lu)vipivotide tetraxetan)。Pluvicto 获批与雄激素剥夺疗法联合使用,无论是否联合雄激素受体通路抑制,用于治疗前列腺特异性膜抗原 (PSMA) 阳性转移性去势抵抗性前列腺癌 (mCRPC) 成年患者。(来源:诺华,新闻稿,2022 年)
放射性药物治疗市场报告范围
报告属性 | 细节 |
---|---|
2023 年的市场规模 | 27.1亿美元 |
2031 年市场规模 | 73亿美元 |
全球复合年增长率(2023 - 2031) | 13.1% |
历史数据 | 2021-2022 |
预测期 | 2024-2031 |
涵盖的领域 | 按产品类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
放射性药物治疗市场报告覆盖范围和交付成果
“放射性药物治疗市场规模和预测(2023-2031)”报告对以下领域进行了详细的市场分析:
- 范围内涵盖的所有主要细分市场的全球、区域和国家层面的市场规模和预测
- 市场动态,如驱动因素、限制因素和关键机遇
- 未来主要趋势
- 详细的 PEST 和 SWOT 分析
- 全球和区域市场分析涵盖关键市场趋势、主要参与者、法规和最新市场发展
- 行业格局和竞争分析,涵盖市场集中度、热点图分析、知名参与者和最新发展
- 详细的公司简介
Radiopharmaceutical Therapeutic Market Report Scope
Report Attribute | Details |
---|---|
Market size in | US$ 2.71 Billion |
Market Size by | US$ 7.30 Billion |
Global CAGR | 13.1% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By 产品类型(锝-99m、铊-201、镓-68、碘-131、铜-64 等) |
Regions and Countries Covered |
北美(美国、加拿大、墨西哥)
|
Market leaders and key company profiles |
|
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
This text is related
to segments covered.
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The radiopharmaceutical therapeutic market majorly consists of the players, including Cardinal Health, Bayer, Novartis, Jubilant DraxImage Inc., Curium, Yantai Dongcheng Pharmaceutical Group, Lantheus, Q BioMed, Telix Pharmaceuticals, and Radiopharm Theranostics.
The radiopharmaceutical therapeutic market is expected to be valued at US$ 7.30 billion in 2031.
The radiopharmaceutical therapeutic market was valued at US$ 2.71 billion in 2023.
The factors driving the growth of the radiopharmaceutical therapeutic market include the growing popularity of targeted therapies and the increasing prevalence of cancer. However, the short shelf-life of radiopharmaceuticals hampers the growth of the radiopharmaceutical therapeutic market.
The global radiopharmaceutical therapeutic market is segmented based on product type, therapy type, application, and end user. The radiopharmaceutical therapeutic market, by product type, is categorized into Technitium-99m, Thallium-201, Gallium-68, Iodine-131, Copper-64, and others. The Technitium-99m segment held a significant market share in 2023 and is anticipated to record the highest CAGR in the market during 2023–2031.
Pharmaceutical substances that include radioactive isotopes that are used to treat cancer and other medical conditions are known as radiopharmaceutical therapeutics. To reduce damage to healthy tissues, these radiopharmaceuticals are made to particularly target and deliver high doses of radiation directly to the site of the disease.
The List of Companies - Radiopharmaceutical Therapeutic Market
- Cardinal Health
- Bayer
- Novartis
- Jubilant DraxImage Inc.
- Curium
- Yantai Dongcheng Pharmaceutical Group
- Lantheus
- Q BioMed
- Telix Pharmaceuticals
- Radiopharm Theranostics.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.